SEC Tracker
Get the app

Possible new TVTX shares

TVTXDilution

Known so far: no new shares from the prospectus covers read · shelf not limited by the baby-shelf rule · not yet read: warrants, ATM.

Shelf room

  • Room today not capped by the baby-shelf rule ($1.3B float, Jun 30, 2025)
How this is worked out

Shelf room on the S-3ASR of Aug 1, 2024: not limited by the baby-shelf rule, because the $1.3B public float stated as of Jun 30, 2025 is $75M or more. Sources: S-3ASR Aug 1, 2024, effective Aug 1, 2024 · public float, as of Jun 30, 2025.

What could become new Travere Therapeutics (TVTX) shares: convertible notes and options and RSUs, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.

TVTX dilution ladder

Every source of new shares on record, from the filings that created it.

96M outstanding; up to 113.6M fully diluted, +18%

  1. Outstandingas of Oct 28, 2026 (10-Q filed Nov 2) · share count on the cover page
    96M
  2. Convertible notes11.1M shares10-Q Nov 2, 2026 · securities left out of diluted EPS
    +11.1M
  3. Options and RSUs6.6M options10-Q Nov 2, 2026 · equity note
    +6.6M

Not stated in the filings we read: an ATM program, warrants.

Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.

Financing terms to know

None found in filings since Oct 30, 2025.

Each term is quoted from the exhibit it comes from; numbers are as stated in the filing. A flag describes a financing term. It is not investment advice.

Shares outstanding

96.0M

Feb 2025 to Oct 2026: from 88.7M to 96.0M.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.